Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital.
Fatma Karapinar ÇarkitRonald van der KnaapFatiha BouhannouchSander D BorgsteedeMarjo J A JanssenCarl E H SiegertToine C G EgbertsPatricia M L A van den BemtMarieke F van WierJudith E BosmansPublished in: PloS one (2017)
The COACH program was not cost-effective in comparison with usual care. Future studies should focus on high risk patients and include other outcomes (e.g. adverse drug events) as this may increase the chances of a cost-effective intervention. Dutch trial register NTR1519.
Keyphrases
- healthcare
- end stage renal disease
- adverse drug
- quality improvement
- ejection fraction
- newly diagnosed
- palliative care
- randomized controlled trial
- peritoneal dialysis
- emergency department
- type diabetes
- study protocol
- metabolic syndrome
- adipose tissue
- patient reported outcomes
- chronic pain
- pain management
- affordable care act
- health insurance
- acute care
- case control
- clinical evaluation